
Biosyent Inc
XTSX:RX

Intrinsic Value
The intrinsic value of one
RX
stock under the Base Case scenario is
12.16
CAD.
Compared to the current market price of 10.5 CAD,
Biosyent Inc
is
Undervalued by 14%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Biosyent Inc
Fundamental Analysis


Revenue & Expenses Breakdown
Biosyent Inc
Balance Sheet Decomposition
Biosyent Inc
Current Assets | 24.5m |
Cash & Short-Term Investments | 15.9m |
Receivables | 3m |
Other Current Assets | 5.5m |
Non-Current Assets | 16.9m |
Long-Term Investments | 10.1m |
PP&E | 1.2m |
Intangibles | 5m |
Other Non-Current Assets | 542.3k |
Free Cash Flow Analysis
Biosyent Inc
CAD | |
Free Cash Flow | CAD |
Earnings Waterfall
Biosyent Inc
Revenue
|
35m
CAD
|
Cost of Revenue
|
-7.2m
CAD
|
Gross Profit
|
27.9m
CAD
|
Operating Expenses
|
-18.8m
CAD
|
Operating Income
|
9.1m
CAD
|
Other Expenses
|
-1.8m
CAD
|
Net Income
|
7.3m
CAD
|
RX Profitability Score
Profitability Due Diligence
Biosyent Inc's profitability score is 70/100. The higher the profitability score, the more profitable the company is.

Score
Biosyent Inc's profitability score is 70/100. The higher the profitability score, the more profitable the company is.
RX Solvency Score
Solvency Due Diligence
Biosyent Inc's solvency score is 99/100. The higher the solvency score, the more solvent the company is.

Score
Biosyent Inc's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
RX Price Targets Summary
Biosyent Inc
According to Wall Street analysts, the average 1-year price target for
RX
is 11.99 CAD
with a low forecast of 11.87 CAD and a high forecast of 12.34 CAD.
Dividends
Current shareholder yield for RX is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
RX
stock under the Base Case scenario is
12.16
CAD.
Compared to the current market price of 10.5 CAD,
Biosyent Inc
is
Undervalued by 14%.